About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a company based in Tarrytown (United States) founded in 1988 by Leonard Schleifer. The company has 15,110 employees as of December 31, 2024. Regeneron Pharmaceuticals has completed 4 acquisitions, including Checkmate Pharmaceuticals, Decibel Therapeutics and LIBTAYO. Regeneron Pharmaceuticals operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter Tarrytown, United States
- Employees 15110 as on 31 Dec, 2024
- Founders Leonard Schleifer
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Regeneron Pharmaceuticals, Inc.
-
Annual Revenue
$14.34 B (USD)0.99as on Dec 31, 2025
-
Net Profit
$4.5 B (USD)2.09as on Dec 31, 2025
-
EBITDA
$4.66 B (USD)-2.37as on Dec 31, 2024
-
Latest Funding Round
$14.86 M (USD), Grant
Aug 28, 2010
- Investors
-
Employee Count
15110
as on Dec 31, 2024
-
Investments & Acquisitions
Checkmate Pharmaceuticals
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol REGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Regeneron Pharmaceuticals
Unlock access to complete
Unlock access to complete
Leadership Team
229 people
Software Development Team
223 people
Senior Team
81 people
Product Management Team
55 people
Legal and Compliance
46 people
Operations Team
43 people
Data Analysis and Operations Team
37 people
Human Resources and Administration
29 people
Unlock access to complete
Funding Insights of Regeneron Pharmaceuticals
Investors in Regeneron Pharmaceuticals
Regeneron Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Regeneron Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Regeneron Pharmaceuticals
Regeneron Pharmaceuticals has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Checkmate Pharmaceuticals, Decibel Therapeutics and LIBTAYO.
Investment portfolio details for Regeneron Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Oligonucleotides for cancer immunotherapy are developed via innate immune activation.
|
Locked | Locked | 2015 | Locked | |
|
Medicines are developed to protect, repair, and restore hearing capacity.
|
Locked | Locked | 2015 | Locked | |
|
Drug delivery platforms and therapeutics for ophthalmology are developed.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for Regeneron Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Regeneron Pharmaceuticals
Detailed financials for Regeneron Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Regeneron Pharmaceuticals Comparisons
Peer comparison for Regeneron Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Regeneron Pharmaceuticals
Regeneron Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Regeneron Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Regeneron Pharmaceuticals
Complete news archive for Regeneron Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regeneron Pharmaceuticals
Regeneron Pharmaceuticals was founded in 1988 and raised its 1st funding round 19 years after it was founded.
Regeneron Pharmaceuticals is headquartered in Tarrytown, United States. It is registered at Tarrytown, New York, United States.
Leonard Schleifer is the current CEO of Regeneron Pharmaceuticals. They have also founded this company.
As of Dec 31, 2024, the latest employee count at Regeneron Pharmaceuticals is 15,110.
Annual revenue of Regeneron Pharmaceuticals is $14.34B as on Dec 31, 2025.
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, United States. Antibodies are developed by the company for applications in oncology, ophthalmology, and immunology. Key products include ARCALYST for inflammation, EYLEA for eye conditions, and PRALUENT as a PCSK9 inhibitor. Phase 3 and 2 pipelines address rheumatoid arthritis, asthma, atopic dermatitis, and other disorders. Annual revenues reached 12.17 billion in 2022, with net profit at 4.33 billion.
Yes, Regeneron Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol REGN.
Regeneron Pharmaceuticals has made 4 acquisitions, including Checkmate Pharmaceuticals, Decibel Therapeutics, and LIBTAYO.
Regeneron Pharmaceuticals has 1 investor. Key investors include HHS.
The ticker symbol of Regeneron Pharmaceuticals is REGN on NASDAQ.